Biomea Fusion, Inc. Stock Price, News & Analysis

Biomea Fusion (NASDAQ:BMEA) presented promising preclinical data for its menin inhibitor icovamenib in combination with semaglutide at the 61st EASD Annual Meeting. The combination therapy demonstrated significant improvements in a Type 2 Diabetes animal model, including a 60% reduction in fasting blood glucose and 50% lower glucose AUC compared to semaglutide alone.

Key findings showed the combination achieved greater body weight reduction (-12.5% vs -3.4%) while preserving lean mass, and improved beta cell function. Additionally, Biomea announced FDA clearance of their IND for BMF-650, their oral GLP-1 receptor agonist, with Phase I obesity trial data expected in H1 2026.

The company plans to advance clinical evaluation of icovamenib with GLP-1 therapies in a Phase II study starting in H2 2025.

Biomea Fusion (Nasdaq: BMEA) reported Q2 2025 financial results and key developments for its diabetes and obesity pipeline. The company presented three significant studies at ADA 2025 highlighting icovamenib's therapeutic potential in type 2 diabetes, showing durable HbA1c reduction and improved beta-cell function. Their next-generation oral GLP-1 receptor agonist, BMF-650, demonstrated up to 15% weight reduction in non-human primates.

The company raised $42.8 million through a public offering, extending cash runway into H2 2026. Q2 2025 resulted in a net loss of $20.7 million, compared to $37.3 million in Q2 2024. Biomea reduced its workforce and expects quarterly operational expenses to be approximately 40% lower than the previous quarter.

Biomea Fusion (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, has appointed Julianne Averill to its Board of Directors, effective July 22, 2025. Averill, who will serve on the Audit Committee, brings over 20 years of experience in life sciences and digital health, currently serving as Managing Director at Danforth Advisors.

The appointment comes as Bihua Chen steps down after more than four years on the board. Averill's expertise includes capital markets, M&A, and operational scale, with involvement in transactions exceeding $10 billion in aggregate value. She holds both B.S. and M.S. degrees from California State University, along with CPA licensure and NACD Directorship Certification.

Biomea Fusion (BMEA) presented promising new data for icovamenib, their oral menin inhibitor, at the ADA Scientific Sessions. In clinical trials, icovamenib demonstrated significant efficacy in type 2 diabetes treatment, achieving a 1.0% placebo-adjusted HbA1c reduction and 55% C-peptide increase in insulin-deficient patients. When combined with low-dose semaglutide in preclinical studies, the treatment showed superior metabolic benefits including enhanced glycemic control, 60% lower fasting blood glucose, and greater body weight reduction while preserving lean mass. The Phase II COVALENT-111 trial revealed sustained benefits even after treatment discontinuation, with particularly strong results in patients using GLP-1 RA therapy. The drug demonstrated good tolerability with no significant adverse events or discontinuations.

Biomea Fusion reported promising preclinical results for BMF-650, their oral GLP-1 receptor agonist candidate for obesity treatment. In a 28-day study with obese cynomolgus monkeys, BMF-650 demonstrated significant weight loss and appetite suppression. The drug, administered orally once daily at 10 mg/kg and 30 mg/kg, achieved average weight reductions of 12% and 15% respectively. Daily food intake decreased dramatically to 35g/day (10 mg/kg) and 16g/day (30 mg/kg) compared to 109g/day in the control group. The drug was generally well-tolerated with no concerning safety signals. Biomea plans to file an IND in H2 2025 and initiate Phase I trials in obese, healthy volunteers by late 2025.

Biomea Fusion (BMEA) has priced its public offering of securities, consisting of 19,450,000 shares of common stock and warrants, plus 550,000 pre-funded warrants with accompanying warrants. The combined offering price is $2.00 per share of common stock with warrant, and $1.9999 for each pre-funded warrant with warrant. The accompanying warrants have an exercise price of $2.50, are immediately exercisable, and expire in 18 months. The offering is expected to generate approximately $40 million in gross proceeds before deductions. Biomea has granted underwriters a 30-day option to purchase up to 3 million additional shares and/or warrants. The offering is expected to close on June 20, 2025, with Jefferies acting as the sole book-running manager.

Biomea Fusion (BMEA), a clinical-stage diabetes and obesity company, has announced a proposed public offering of common stock and warrants. The offering includes shares of common stock, pre-funded warrants, and accompanying warrants to purchase common stock. Biomea will grant underwriters a 30-day option to purchase up to 15% additional shares and pre-funded warrants. Jefferies is serving as the sole book running manager for the offering, which is expected to close around June 20, 2025. The securities will be offered through an effective shelf registration statement on Form S-3 filed with the SEC. The final size, terms, and completion of the offering are subject to market conditions.

Biomea Fusion (NASDAQ: BMEA) presented updated clinical data for BMF-500, their covalent FLT3 inhibitor, in treating relapsed/refractory acute leukemia. The Phase I COVALENT-103 trial included 27 heavily pretreated patients, with 18 having FLT3 mutations. Key findings showed 9 of 11 evaluable FLT3m patients achieved bone marrow blast reduction, with one patient achieving complete remission with incomplete hematologic recovery (CRi) sustained for 6 cycles. The median overall survival was 3.8 months in Arm A and 3.5 months in Arm B, comparing favorably to historical 2.1 months survival. BMF-500 demonstrated good tolerability with no dose-limiting toxicities or QT prolongation. Following dose escalation completion, Biomea plans to conclude internal development and seek strategic partnerships for the program's advancement.

Biomea Fusion (BMEA) announced that preliminary Phase I data for BMF-500, their covalent FLT3 inhibitor, will be presented at the EHA 2025 Congress in Milan. The COVALENT-103 trial shows promising results in relapsed/refractory acute leukemia patients. Key findings include:

• 24 patients enrolled, with 15 having FLT3 mutations
• 81.8% of evaluable patients showed clinical activity
• 77.8% demonstrated decreased bone marrow blasts
• Median overall survival of 3.48 months vs. historical 2.1 months
• Well-tolerated safety profile with no treatment-related discontinuations

Despite these positive results, Biomea plans to conclude internal development of BMF-500 in oncology and is seeking strategic partnerships, as the company shifts focus to metabolic diseases.